227029-27-8

Basic information

• Product Name: 2-(5-METHYL-2-PHENYL-1,3-OXAZOL-4-YL)ETHYL METHANESULFONATE
• Synonyms: 2-(5-METHYL-2-PHENYL-1,3-OXAZOL-4-YL)ETHYL METHANESULFONATE;2-(5-METHYL-2-PHENYL-4-OXAZOLYL)ETHYL METHANESULFONATE;4-Oxazoleethanol, 5-Methyl-2-phenyl-, 4-Methanesulfonate;2-(5-methyl-2-phenyloxazol-4-yl)ethyl methanesulfonate;Methanesulfonic acid 2-(5-methyl-2-phenyloxazol-4-yl)ethyl ester
• CAS NO: 227029-27-8
• Molecular Formula: C₁₃H₁₅NO₄S
• Molecular Weight: 281.33
• Mol File: 227029-27-8.mol

Chemical Properties

• Boiling Point: 490.381°C at 760 mmHg
• Flash Point: 250.373°C
• Appearance: /
• Density: 1.257g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.546
• PKA: 0.96±0.26(Predicted)
• CAS DataBase Reference: 2-(5-METHYL-2-PHENYL-1,3-OXAZOL-4-YL)ETHYL METHANESULFONATE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(5-METHYL-2-PHENYL-1,3-OXAZOL-4-YL)ETHYL METHANESULFONATE(227029-27-8)
• EPA Substance Registry System: 2-(5-METHYL-2-PHENYL-1,3-OXAZOL-4-YL)ETHYL METHANESULFONATE(227029-27-8)

Safety Data

• Hazardous Substances Data: 227029-27-8(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
2-(5-METHYL-2-PHENYL-1,3-OXAZOL-4-YL)ETHYL METHANESULFONATE is used as a protecting group for alcohols in organic synthesis for its ability to allow selective deprotection under specific reaction conditions, facilitating the synthesis of complex organic molecules.
Used in Pharmaceutical Synthesis:
In the pharmaceutical industry, 2-(5-METHYL-2-PHENYL-1,3-OXAZOL-4-YL)ETHYL METHANESULFONATE is used as a precursor in the synthesis of various pharmaceuticals, contributing to the development of new drugs and medicinal compounds.
Used in Chemical Research:
2-(5-METHYL-2-PHENYL-1,3-OXAZOL-4-YL)ETHYL METHANESULFONATE is utilized in chemical research for studying the properties and reactions of 1,3-oxazole derivatives and their potential applications in the creation of new chemical entities.

InChI:InChI=1/C13H15NO4S/c1-10-12(8-9-17-19(2,15)16)14-13(18-10)11-6-4-3-5-7-11/h3-7H,8-9H2,1-2H3

Upstream product

• 124-63-0 methanesulfonyl chloride 
• 103788-65-4 (5-methyl-2-phenyloxazol-4-yl)ethanol 
• 27492-46-2 4,5-dimethyl-2-phenyl-oxazole 3-oxide 
• 100-52-7 benzaldehyde 
• 103788-61-0 (5-methyl-2-phenyl-4-oxazolyl)methyl chloride 
• 107367-98-6 2-(5-Methyl-2-phenyl-4-oxazolyl)-acetic acid 
• 524959-64-6 2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)acetonitrile 
• 103788-64-3 methyl 2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)acetate 
• 98-88-4 benzoyl chloride 
• 2198-64-3 N-Benzoylalanine 
• 100718-97-6 ethyl 4-(benzoylamino)-3-oxopentanoate 
• 114564-74-8 ethyl (4-methyl-2-phenyl-1,3-oxazol-5-yl)acetate 
• 17944-68-2 2-(4-methyl-2-phenyl-1,3-oxazol-5-yl)ethanol 

Downstream Products

• 159018-02-7 methyl 3-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]propionate 
• 604006-48-6 7-[2-(5-methyl-2-phenyl-oxazol-4-yl)-ethoxy]-2-oxo-2H-chromene-3-carboxylic acid ethyl ester 
• 604006-36-2 N-{7-[2-(5-methyl-2-phenyl-oxazol-4-yl)-ethoxy]-2-oxo-2H-chromen-3-yl}-acetamide 
• 103788-59-6 4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]benzaldehyde 
• 851179-99-2 3-methoxyimino-2-{4-[2-(5-methyl-2-phenyl-oxazole-4-yl)-ethoxy]-benzyl}-butyric acid methyl ester 
• 932024-99-2 3-methoxyimino-2-{4-[2-(5-methyl-2-phenyl-oxazol-4-yl)-ethoxy]-benzyl}-pentanoic acid methyl ester 
• 932024-94-7 3-ethoxyimino-2-{4-[2-(5-methyl-2-phenyl-oxazol-4-yl)-ethoxy]-benzyl}-butyric acid methyl ester 
• 932025-00-8 3-ethoxyimino-2-{4-[2-(5-methyl-2-phenyl-oxazol-4-yl)-ethoxy]-benzyl}-pentanoic acid methyl ester 
• 932024-96-9 3-isobutoxyimino-2-{4-[2-(5-methyl-2-phenyl-oxazol-4-yl)-ethoxy]-benzyl}-butyric acid methyl ester 
• 932024-95-8 2-{4-[2-(5-methyl-2-phenyl-oxazol-4-yl)-ethoxy]-benzyl}-3-propoxyimino-butyric acid methyl ester 
• 932024-98-1 3-cyclopropylmethoxyimino-2-{4-[2-(5-methyl-2-phenyl-oxazol-4-yl)-ethoxy]-benzyl}-butyric acid methyl ester 
• 932024-97-0 3-butoxyimino-2-{4-[2-(5-methyl-2-phenyl-oxazol-4-yl)-ethoxy]-benzyl}-butyric acid methyl ester 
• 932025-01-9 3-(4-fluoro-benzyloxyimino)-2-{4-[2-(5-methyl-2-phenyl-oxazol-4-yl)-ethoxy]-benzyl}-butyric acid methyl ester 
• 244152-94-1 3-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzaldehyde 

Relevant articles and documents

Synthesis of JTT-501 and its metabolite JTP-20604 labelled with 13C

JTT-501 specifically labelled with 13C was obtained via a four-step synthesis at an isotopic enrichment level of 99% and in 14% overall chemical yield starting from 4-hydroxy-[ring-U-13C6]benzaldehyde (3). The hydrogenatio

Convenient Continuous Flow Synthesis of N-Methyl Secondary Amines from Alkyl Mesylates and Epoxides

The first continuous flow process was developed to synthesize N-methyl secondary amines from alkyl mesylates and epoxides via a nucleophilic substitution using aqueous methylamine. A variety of N-methyl secondary amines were produced in good to excellent yields, including a number of bioactive compounds or their precursors. Up to 10.6 g (88% yield) of an N-methyl secondary amine was produced in 140 min process time. The amination procedure included an in-line workup, and the starting mesylate material was also produced in continuous flow from the corresponding alcohol. Finally, an in-line process combining the mesylate synthesis and nucleophilic substitution was developed.

METHODS OF TREATING OR PREVENTING COGNITIVE IMPAIRMENT USING INDANE ACETIC ACID DERIVATIVES BASED ON APOE4 GENOTYPE

The present invention provides indane acetic acid and their derivatives and methods for the treating and/or preventing of cognitive disorders based on the ApoE4 genotype of human subjects.

METHODS OF DOSE ADMINISTRATION FOR TREATING OR PREVENTING COGNITIVE IMPAIRMENT USING INDANE ACETIC ACID DERIVATIVES

The present invention provides indane acetic acid and their derivatives and methods for the treating and/or preventing of cognitive disorders.

Design and synthesis of Oxime ethers of β-oxo-γ-phenylbutanoic acids as PPAR a and -γ dual agonists

Oxime ethers of p-oxo-y-phenylbutanoic acids were prepared to develop more effective PPAR a and y dual agonists. Among them, compound 11k exhibited potent in vitro activities with EC50 of 2.5 nM and 3.3 nM in PPAR a and y, respectively. It showed better g

Synthesis and antimicrobial evaluation of 3-methanone-6-substituted- benzofuran derivatives

Seventeen benzofuran derivatives were synthesized and screened for their antibacterial activities against Escherichia coli, Staphylococcus aureus, Methicillin-resistant S. aureus, Bacillus subtilis, and Pseudomonas aeruginosa. Seven of them have showed excellent antibacterial activities compared to the positive controls (Cefotaxime and Sodium Penicillin). The substitutions at C-6 and C-3 positions of these derivatives were found to greatly impact on the antibacterial activity and strains specificity, respectively. Specifically, compounds bearing a hydroxyl group at C-6 (5a, 5b, 5c and 12) offered excellent antibacterial activities against all five above-mentioned strains (MIC 80 = 0.78-12.5 ug/mL), and those with imine (15) and (3, 4, 5-trimethoxyphenyl) methanone (7e), respectively, at C-3 position showed selective activity against S. aureus among five tested strains with great MIC80 values (3.12-12.5 ug/mL).

In vitro SAR of pyrrolidine-containing histamine H3 receptor antagonists: Trends across multiple chemical series

Structure-activity relationships (SAR) were analyzed within a library of diverse yet simple compounds prepared as histamine H3 antagonists. The libraries were constructed with a variety of low molecular weight pyrrolidines, selected from (R)-2-methylpyrrolidine, (S)-2-methylpyrrolidine, and pyrrolidine.

Design and synthesis of oxime ethers of α-acyl-β-phenylpropanoic acids as PPAR dual agonists

Oxime ethers of α-acyl-β-phenylpropanoic acids were prepared to apply as PPARα and γ dual agonists. Among them, compound 11l proved to exhibit potent in vitro activities with EC50 of 19 and 13 nM in PPARα and γ, respectively. It showed better g

Design and synthesis of N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl- 2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]glycine [muraglitazar/BMS-298585], a novel peroxisome proliferator-activated receptor α/γ dual agonist with efficacious glucose and lipid-l

Muraglitazar/BMS-298585 (2) has been identified as a non-thiazolidinedione PPAR α/γ dual agonist that shows potent activity in vitro at human PPARα (EC50 = 320 nM) and PPARγ (EC50 = 110 nM). Compound 2 shows excellent efficacy for lo

ORGANIC COMPOUNDS

Compounds of the formula (I) provide pharmacological agents which bind to Peroxisome Proliferator-Activated Receptors (PPARs). Accordingly, the compounds of the present invention are useful for the treatment of conditions mediated by the PPAR receptor activity in mammals. Such conditions include dyslipidemia, hyperlipidemia, hypercholesteremia, atherosclerosis, hypertriglyceridemia, heart failure, myocardial infarction, vascular diseases, cardiovascular diseases, hypertension, obesity, inflammation, arthritis, cancer, Alzheimer's disease, skin disorders, respiratory diseases, ophthalmic disorders, inflammatory bowel diseases (IBDs), ulcerative colitis and Crohn's disease. The compounds of the present invention are particularly useful in mammals as hypoglycemic agents for the treatment and prevention of conditions in which impaired glucose tolerance, hyperglycemia and insulin resistance are implicated, such as type-1 and type-2 diabetes, and Syndrome X.